Prussian Blue Nanoparticles Promoting Diabetic Bone Regeneration via Mitochondrial Recovery

Area of Science:

• Biomaterials Science
• Nanotechnology
• Regenerative Medicine

Background:

• Type 2 diabetes (T2D) increases fracture risk due to hyperglycemia-induced oxidative stress.
• Oxidative stress impairs mitochondrial function, leading to bone marrow mesenchymal stem cell (BMSC) senescence and reduced osteogenesis.
• Existing antioxidant therapies face limitations, creating a need for novel strategies.

Purpose of the Study:

• To develop Prussian blue (PB) nanoparticles as nanozymes to mitigate BMSC senescence and bone loss in T2D.
• To investigate the therapeutic potential of PB nanoparticles in restoring bone quality.

Main Methods:

• Synthesis and characterization of PB nanoparticles.
• In vitro evaluation using a high glucose/palmitate-induced diabetic BMSC model.
• Assessment of ROS scavenging, mitochondrial function, senescence, and osteogenic potential.
• In vivo validation of bone loss attenuation in a T2D mouse model.

Main Results:

• PB nanoparticles effectively scavenged reactive oxygen species (ROS).
• They rebalanced mitochondrial dynamics, suppressed BMSC senescence, and restored osteogenic capacity.
• PB nanoparticles significantly attenuated bone loss in vivo in a T2D mouse model.

Conclusions:

• PB nanoparticles represent a promising nanozyme-based therapeutic strategy for T2D.
• This approach effectively addresses BMSC senescence and bone loss, improving bone quality.
• The findings offer an innovative solution for managing bone health in diabetic patients.